RxDoctor Payments DataLook up a doctor →

David Morris, MD

Hematology & Oncology · Hattiesburg, MSNPI 1477595643

Payments from drug & device makers

$5,539in general payments, 2019–2025

Across 258 payments — averaging $21.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$622
  • Astellas Pharma US Inc$568
  • Gilead$388
  • Pfizer$317
  • Bristol Myers Squibb$294
  • E.r. Squibb & Sons, L.L.C.$276
  • plus $3K from 42 others

What the payments were for

  • Travel & lodging$671%
  • Food & beverage$5,17393%
  • Education$3005%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,539 in reported general payments places this provider in the 25th percentile of 57 hematology & oncology providers in Mississippi.

See all hematology & oncology providers in Mississippi

Medicare billing

Part B allowed, 2024
$4,214,734
Medicare patients
638
Services billed
222,692

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide18$412,439
ImbruvicaIbrutinib20$316,777
IbrancePalbociclib14$230,067
XtandiEnzalutamide16$215,560
PemazyrePemigatinib11$207,337
JakafiRuxolitinib Phosphate11$179,757
Imatinib Mesylate42$44,717
XareltoRivaroxaban11$10,630
Anastrozole315$5,101
Anagrelide Hcl19$5,069
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen76$2,261
Hydroxyurea73$1,492
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen41$1,127
Ondansetron Hcl124$1,009
Morphine Sulfate ErMorphine Sulfate32$914

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$276$412,43918 claims
Incyte CorporationPemazyre, Jakafi$184$387,09322 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$106$316,77720 claims
PfizerIbrance$317$230,06714 claims
Astellas Pharma US IncXtandi$568$215,56016 claims
Johnson & JohnsonXarelto$622$10,63011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 57 hematology & oncology providers in Mississippi.

Other hematology & oncology in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →